Sarepta Therapeutics Inc (SRPT) was Reiterated by RBC Capital Mkts to “Sector Perform” while Lowering the Price Target of the company shares to $ 5 from a previous price target of $7.50 . RBC Capital Mkts advised their investors in a research report released on Apr 26, 2016.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Sector Perform” and Lowered the Price Target to $ 7.50 from a previous price target of $14 .Sarepta Therapeutics Inc was Downgraded by JMP Securities to ” Mkt Underperform” on Mar 23, 2016. Shares were Reiterated by Needham on Mar 1, 2016 to “Buy” and Lowered the Price Target to $ 53 from a previous price target of $55 .
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.30 EPS for the quarter, missing the analyst consensus estimate by $ -0.13 based on the information available during the earnings call on Feb 25, 2016. Analyst had a consensus of $-1.17. The company had revenue of $1.25 million for the quarter.The company’s revenue was up 4066.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.94 EPS.
Sarepta Therapeutics Inc opened for trading at $11.41 and hit $15.7 on the upside on Friday, eventually ending the session at $14.95, with a gain of 35.66% or 3.93 points. The heightened volatility saw the trading volume jump to 3,13,22,751 shares. Company has a market cap of $683 M.
In a different news, on Mar 16, 2016, M Kathleen Behrens (director) purchased 75,000 shares at $15.54 per share price. According to the SEC, on Mar 16, 2016, Ben Gil Price (director) purchased 4,500 shares at $16.70 per share price. On Mar 16, 2016, Richard Barry (director) purchased 75,000 shares at $15.66 per share price, according to the Form-4 filing with the securities and exchange commission.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.